Related Experiment Video
Updated: Jun 26, 2026
10:37
Ferric Chloride-induced Murine Thrombosis Models
Published on: September 5, 2016
Advances in antiplatelet therapy: agents in clinical development
Dominick J Angiolillo1, Deepak L Bhatt, Paul A Gurbel
1Division of Cardiology, University of Florida College of Medicine-Jacksonville, Jacksonville, Florida, USA.
The American Journal of Cardiology
|January 27, 2009
Summary
Standard antiplatelet therapy with aspirin and clopidogrel isn't always effective, leading to treatment failure. New antiplatelet agents are being investigated as alternatives to improve patient outcomes in acute coronary syndromes.
Area of Science:
- Cardiology
- Pharmacology
- Thrombosis
Background:
- Antiplatelet agents are crucial for managing acute coronary syndromes and percutaneous coronary intervention.
- Current standard therapy combines aspirin and clopidogrel, but suboptimal responses and resistance occur.
- Drug resistance can lead to treatment failure and atherothrombotic events.
Purpose of the Study:
- To review emerging antiplatelet agents.
- To explore alternatives to the current aspirin-clopidogrel regimen.
- To address limitations of standard antiplatelet therapy.
Main Methods:
- Literature review of current and investigational antiplatelet therapies.
- Analysis of pharmacokinetic and pharmacodynamic properties of new agents.
- Comparison of novel agents with standard dual antiplatelet therapy.
Main Results:
- Several new antiplatelet agents show promise.
- Prasugrel offers improved pharmacokinetics over clopidogrel.
- Ticagrelor and cangrelor represent alternative mechanisms of action.
- Thrombin receptor antagonists are also under investigation.
Conclusions:
- Optimal antiplatelet therapy remains an area of active research.
- New agents may overcome resistance and improve outcomes.
- Personalized antiplatelet strategies may be necessary.
Related Concept Videos
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:27Peripheral Artery Disease III: Interprofessional Care
Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
01:27Coronary Artery Disease V: Interprofessional Care
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
01:26Atherosclerosis III: Management
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...